Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0211 | 0.3386 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0211 | 0.3386 | 0.3341 |
Schistosoma mansoni | nAChR subunit (ShAR1-beta-like) | 0.0211 | 0.3386 | 1 |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0586 | 1 | 1 |
Mycobacterium ulcerans | glutamine-binding lipoprotein GlnH | 0.0019 | 0 | 0.5 |
Chlamydia trachomatis | glutamine binding protein | 0.0019 | 0 | 0.5 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0026 | 0.0128 | 1 |
Brugia malayi | Cation transporter family protein | 0.0211 | 0.3386 | 0.3341 |
Schistosoma mansoni | nAChR subunit (ShAR1-alpha-like) | 0.0211 | 0.3386 | 1 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.0026 | 0.0128 | 1 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0019 | 0 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0026 | 0.0128 | 1 |
Onchocerca volvulus | 0.0211 | 0.3386 | 1 | |
Onchocerca volvulus | 0.0211 | 0.3386 | 1 | |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0211 | 0.3386 | 0.3341 |
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | NNMT/PNMT/TEMT family protein | 0.0586 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0586 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0195 | 0.3117 | 0.307 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 12 % | DNDI: Inhibition of Human African Trypanosomiasis, SBRI 427, in vitro at 2 ug.mL-1 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.